Zevra Therapeutics, Inc. (ZVRA) – What Are Investment Firms Saying About This Stock?

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given an average recommendation of “Buy” by the eleven research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $27.14.

Several analysts have recently issued reports on ZVRA shares. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Zevra Therapeutics in a report on Wednesday, August 19th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. BTIG Research cut their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Finally, UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th.

Insiders Place Their Bets

In related news, Director Corey Watton sold 12,300 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the sale, the director owned 1,800 shares in the company, valued at $20,250. This represents a 87.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Neil F. Mcfarlane sold 20,000 shares of the company’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the transaction, the chief executive officer owned 417,225 shares of the company’s stock, valued at $4,693,781.25. This trade represents a 4.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Fulcrum Asset Management LLP acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $31,000. Alps Advisors Inc. bought a new position in shares of Zevra Therapeutics in the third quarter valued at $528,000. Integrity Alliance LLC. bought a new position in Zevra Therapeutics during the third quarter valued at approximately $10,292,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $33,000. Finally, Profund Advisors LLC boosted its stake in Zevra Therapeutics by 605.6% in the third quarter. Profund Advisors LLC now owns 109,547 shares of the company’s stock valued at $1,202,000 after acquiring an additional 94,021 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Zevra Therapeutics

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: HC Wainwright increased its EPS estimates for Q4 2026 to $0.14 from $0.13, FY2026 to $0.91 from $0.68, and FY2027 to $0.66 from $0.55. It also lifted estimates for FY2028–FY2030 and retained a Buy rating with a $26 target. The upward revisions point to improved analyst expectations for future earnings.
• Positive Sentiment: Cantor Fitzgerald kept its Buy rating on Zevra Therapeutics, reinforcing the positive analyst outlook. Cantor Fitzgerald Keeps Their Buy Rating on Zevra Therapeutics
• Positive Sentiment: BTIG also gave Zevra a Buy rating, adding to the favorable analyst sentiment. Zevra Therapeutics Receives a Buy from BTIG

Zevra Therapeutics Stock Up 10.1%

Shares of Zevra Therapeutics stock opened at $11.59 on Monday. The firm has a market cap of $688.21 million, a price-to-earnings ratio of 6.39 and a beta of 1.01. The business has a fifty day simple moving average of $11.07 and a 200-day simple moving average of $10.78. Zevra Therapeutics has a fifty-two week low of $8.01 and a fifty-two week high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The company had revenue of $37.76 million during the quarter, compared to the consensus estimate of $37.08 million. Analysts anticipate that Zevra Therapeutics will post 0.87 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.